Switch to dolutegravir raises the risk of potentially harmful weight gain, four-country African study finds
Rapid weight gain after switching to TAF, regardless of other HIV drugs taken
People with HIV gain weight faster than HIV-negative people
Non-alcoholic fatty liver disease affects a quarter of lean people living with HIV
People switching from TDF to TAF experience rising cholesterol levels
Changes in fat cells on HIV treatment may have long-term metabolic consequences
Weight gain after starting HIV treatment may have genetic influences
New mothers with HIV gain more weight on dolutegravir than efavirenz
Weight gain on antiretroviral treatment raises risk of diabetes
